Aspire Biopharma stockholders approve meeting items
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where a quorum of stockholders voted on several proposals.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where a quorum of stockholders voted on several proposals. The 8-K reports that all matters presented at the meeting were approved based on the tabulated voting results.
The disclosed proposals received votes in favor ranging from 1,466,141 to 2,096,356, with varying levels of opposition, abstentions, and broker non-votes. The filing confirms the outcomes of these stockholder votes and is signed by Chief Executive Officer Kraig Higginson.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Top proposal votes for: 2,096,356 votes
Top proposal votes against: 582,185 votes
Top proposal abstentions: 12,852 votes
+4 more
7 metrics
Top proposal votes for
2,096,356 votes
Highest votes for any proposal at April 10, 2026 meeting
Top proposal votes against
582,185 votes
Opposition on highest-supported proposal
Top proposal abstentions
12,852 votes
Abstain votes on highest-supported proposal
Proposal votes for (example)
1,466,141 votes
Votes for on one additional proposal with broker non-votes
Broker non-votes (example)
1,012,844 votes
Broker non-votes recorded on two proposals
Other proposal votes for
1,925,368 votes
Votes for on another proposal at the meeting
Other proposal votes against
551,855 votes
Opposition on another proposal at the meeting
Key Terms
Special Meeting of Stockholders, broker non-votes, Emerging growth company, Common Stock, par value $0.0001 per share, +1 more
5 terms
Special Meeting of Stockholders financial
"On April 10, 2026, at the Special Meeting of Stockholders (the “Meeting”)"
A special meeting of stockholders is an unscheduled gathering called to let shareholders vote on specific, often urgent company decisions—like mergers, major asset sales, changes to the board, or amendments to governing rules. Think of it as an emergency town hall where owners cast ballots in person or by mail/online; outcomes can materially change a company’s strategy, control or value, so investors pay close attention and may need to vote or adjust holdings accordingly.
broker non-votes financial
"Votes For | Votes Against | Votes Abstain | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Emerging growth company regulatory
"Emerging growth company Item 5.07 Submission of Matters"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded with the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aspire Biopharma (ASBP) disclose in this 8-K filing?
Aspire Biopharma reported the voting results from its April 10, 2026 Special Meeting of Stockholders. Multiple proposals were approved, with votes in favor ranging from 1,466,141 to 2,096,356, alongside recorded votes against, abstentions, and broker non-votes.
What are broker non-votes in Aspire Biopharma’s 2026 special meeting results?
Broker non-votes are shares held by brokers that were not voted on certain proposals. In Aspire Biopharma’s April 10, 2026 results, some proposals show broker non-votes up to 1,012,844 shares, indicating brokers did not vote those shares on specific items.
Who signed Aspire Biopharma’s April 2026 8-K about stockholder voting?
The 8-K summarizing the April 10, 2026 Special Meeting voting results was signed on behalf of Aspire Biopharma Holdings, Inc. by Chief Executive Officer Kraig Higginson, confirming the company’s authorization of the reported stockholder vote outcomes.
On which exchange is Aspire Biopharma (ASBP) listed and what securities trade?
Aspire Biopharma’s common stock, par value $0.0001 per share, trades under the symbol ASBP on The Nasdaq Stock Market LLC. Warrants, each exercisable for one share of common stock, trade on Nasdaq under the symbol ASBPW.
What voting range did other Aspire Biopharma proposals receive at the meeting?
Other proposals received votes for between 1,466,141 and 1,925,368 shares, with votes against up to 551,855 and abstentions up to 11,679. Broker non-votes ranged from 0 to 1,012,844, showing varied turnout across the different agenda items.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates